Literature DB >> 7840580

Pharmacokinetics of ceftriaxone in patients with typhoid fever.

G Acharya1, C Crevoisier, T Butler, M Ho, M Tiwari, K Stoeckel, C A Bradley.   

Abstract

Ceftriaxone in short courses has emerged as an effective alternative to chloramphenicol for the treatment of typhoid fever. To study the pharmacokinetics of ceftriaxone in acute typhoid fever, 10 febrile Nepalese adolescents and young adults with blood culture-positive illness were treated with 3 g of ceftriaxone (intravenous infusion for 30 min) daily for 3 days. On the 1st and 3rd day of treatment, blood and urine samples were collected at defined intervals for measurements of drug concentrations. Kinetic parameters including concentrations at the end of infusion (Cmax) and 24 h after the end of infusion (Cmin), elimination half-life (t1/2), area under the plasma concentration-time curve (AUC), total plasma clearance, renal clearance, percentage excreted in urine, and volume of distribution were estimated. On day 1, mean values were as follows: Cmax, 291 micrograms/ml; Cmin, 21.7 micrograms/ml; plasma t1/2, 5.2 h; AUC, 1,428 micrograms.h/ml; total plasma clearance, 37 ml/min; renal clearance, 19 ml/min; percentage excreted in urine, 49.7%; and volume of distribution, 16.1 liters. Mean values on day 3 were not significantly different from those on day 1. Compared with published values for healthy volunteers who received the same dose, our mean t1/2s and AUCs were lower and our mean total plasma clearances, renal clearances, and volumes of distribution were higher. The good clinical responses of these patients to therapy and the adequate Cmins support the use of ceftriaxone once daily for the treatment of typhoid fever.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840580      PMCID: PMC284754          DOI: 10.1128/AAC.38.10.2415

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Therapy of multidrug resistant typhoid in 58 children.

Authors:  S H Naqvi; Z A Bhutta; B J Farooqui
Journal:  Scand J Infect Dis       Date:  1992

2.  The pharmacokinetics of ceftriaxone in serum, skin blister and thread fluid.

Authors:  T Kalager; A Digranes; T Bergan; C O Solberg
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

3.  A study of the relationship between dose and pharmacokinetics of ceftriaxone.

Authors:  C D Findlay; R M Brown; J E Allcock; P A Lowe; R Wise
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

4.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

5.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Sounding board. Why are toxic reactions to drugs so often undetected initially?

Authors:  E S Vesell
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

7.  Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life.

Authors:  K Stoeckel
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

8.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

9.  Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection.

Authors:  P A Anton; J A Kemp; T Butler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

10.  Ceftriaxone therapy in bacteremic typhoid fever.

Authors:  T Y Ti; E H Monteiro; S Lam; H S Lee
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more
  3 in total

1.  Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

Authors:  D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 2.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

3.  Prevalence and antimicrobial susceptibility patterns of Salmonella and Shigella isolates among children aged below five years with diarrhea attending Robe General Hospital and Goba Referral Hospital, South East Ethiopia.

Authors:  Addisu Assefa; Mengistu Girma
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.